Functional switching of TGF-beta1 signaling in liver cancer via epigenetic modulation of a single CpG site in TTP promoter.

BACKGROUND & AIMS Acquisition of resistance to the antiproliferative effect of transforming growth factor (TGF)-beta1 is crucial for the malignant progression of cancers. In this study, we sought to determine whether deregulated expression of tristetrapolin (TTP), a negative posttranscriptional regulator of c-Myc, confers resistance to the antiproliferative effects of TGF-beta1 on liver cancer cells. METHODS The epigenetics of TTP promoter regulation and its effects on TGF-beta1 signaling were examined in hepatocellular carcinoma (HCC) cell lines and patient tissues. RESULTS TTP was down-regulated in HCC cell lines (10/11), compared with normal liver, as well as in tumor tissues (19/24) from paired HCC specimens. Methylation of a specific single CpG site located within the TGF-beta1-responsive region (TRR) of the TTP promoter was significantly associated with TTP down-regulation in both HCC cell lines and tumor tissues (r = -0.606383, P < .001). The singly methylated CpG site was specifically bound by a transcriptional repressor complex consisting of MECP2/c-Ski/DNMT3A and abolished the TGF-beta1-induced as well as basal-level expression of TTP. The epigenetic inactivation of TTP led to an increased half-life of c-Myc mRNA and blocked the cytostatic effect of TGF-beta1. Statistically significant correlations were observed between the single CpG site methylation and expression levels of TTP or c-Myc in clinical samples of HCC. CONCLUSIONS Abrogation of the post-transcriptional regulation of c-Myc via methylation of a specific single CpG site in the TTP promoter presents a novel mechanism for the gain of selective resistance to the antiproliferative signaling of TGF-beta1 in HCC.

[1]  Edsel A. Peña,et al.  The mRNA binding proteins HuR and tristetraprolin regulate cyclooxygenase 2 expression during colon carcinogenesis. , 2009, Gastroenterology.

[2]  K. Zatloukal,et al.  miR‐29a suppresses tristetraprolin, which is a regulator of epithelial polarity and metastasis , 2009, EMBO reports.

[3]  Tom R. Mayo,et al.  Genome-wide Analysis Identifies Interleukin-10 mRNA as Target of Tristetraprolin* , 2008, Journal of Biological Chemistry.

[4]  G. Pagès,et al.  Tristetraprolin inhibits Ras-dependent tumor vascularization by inducing vascular endothelial growth factor mRNA degradation. , 2007, Molecular biology of the cell.

[5]  Hui Zeng,et al.  Correlation between the single-site CpG methylation and expression silencing of the XAF1 gene in human gastric and colon cancers. , 2006, Gastroenterology.

[6]  J. Seoane.  Escaping from the TGFβ anti-proliferative control , 2006 .

[7]  R. Vartanian,et al.  Tristetraprolin regulates Cyclin D1 and c-Myc mRNA stability in response to rapamycin in an Akt-dependent manner via p38 MAPK signaling , 2006, Oncogene.

[8]  E. Cheung,et al.  Smads orchestrate specific histone modifications and chromatin remodeling to activate transcription , 2006, The EMBO journal.

[9]  L. Mahadevan,et al.  Enhanced histone acetylation and transcription: a dynamic perspective. , 2006, Molecular cell.

[10]  Jianzhu Chen,et al.  Inhibition of IFN‐γ transcription by site‐specific methylation during T helper cell development , 2006 .

[11]  B. Sohn,et al.  Deregulation of DNA methyltransferases and loss of parental methylation at the insulin‐like growth factor II (Igf2)/H19 loci in p53 knockout mice prior to tumor development , 2005, Journal of cellular biochemistry.

[12]  J. Lykke-Andersen,et al.  Recruitment and activation of mRNA decay enzymes by two ARE-mediated decay activation domains in the proteins TTP and BRF-1. , 2005, Genes & development.

[13]  K. Ogawa,et al.  Transcriptional Regulation of Tristetraprolin by Transforming Growth Factor-β in Human T Cells* , 2003, Journal of Biological Chemistry.

[14]  G. Stoecklin,et al.  A novel mechanism of tumor suppression by destabilizing AU-rich growth factor mRNA , 2003, Oncogene.

[15]  Beth Y Karlan,et al.  Loss of c-myc repression coincides with ovarian cancer resistance to transforming growth factor beta growth arrest independent of transforming growth factor beta/Smad signaling. , 2003, Cancer research.

[16]  Stella Pelengaris,et al.  c-MYC: more than just a matter of life and death , 2002, Nature Reviews Cancer.

[17]  J. Greenblatt,et al.  Regulation of transcription elongation by phosphorylation. , 2002, Biochimica et biophysica acta.

[18]  M. Turker.  Gene silencing in mammalian cells and the spread of DNA methylation , 2002, Oncogene.

[19]  Peter A. Jones,et al.  The fundamental role of epigenetic events in cancer , 2002, Nature Reviews Genetics.

[20]  A. Raghavan,et al.  HuA and Tristetraprolin Are Induced following T Cell Activation and Display Distinct but Overlapping RNA Binding Specificities* , 2001, The Journal of Biological Chemistry.

[21]  P. Wade.  Methyl CpG‐binding proteins and transcriptional repression * , 2001, BioEssays : news and reviews in molecular, cellular and developmental biology.

[22]  T. Blackwell,et al.  Similar but distinct effects of the tristetraprolin/TIS11 immediate-early proteins on cell survival , 2000, Oncogene.

[23]  K. Miyazono,et al.  c-Ski Acts as a Transcriptional Co-repressor in Transforming Growth Factor-β Signaling through Interaction with Smads* , 1999, The Journal of Biological Chemistry.

[24]  P. Blackshear,et al.  Feedback Inhibition of Macrophage Tumor Necrosis Factor-α Production by Tristetraprolin , 1998 .

[25]  B. Haynes,et al.  A pathogenetic role for TNF alpha in the syndrome of cachexia, arthritis, and autoimmunity resulting from tristetraprolin (TTP) deficiency. , 1996, Immunity.

[26]  D. Stumpo,et al.  Rapid insulin-stimulated accumulation of an mRNA encoding a proline-rich protein. , 1990, The Journal of biological chemistry.

[27]  R. Coffey,et al.  Selective inhibition of growth-related gene expression in murine keratinocytes by transforming growth factor beta , 1988, Molecular and cellular biology.

[28]  T. Mosmann.  Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. , 1983, Journal of immunological methods.

[29]  J. Massagué,et al.  Inaugural Article: Defective repression of c-myc in breast cancer cells: A loss at the core of the transforming growth factor beta growth arrest program , 2001 .

[30]  A. Balmain,et al.  TGF-β signaling in tumor suppression and cancer progression , 2001, Nature Genetics.

[31]  Transforming Growth Factor (cid:2) -Mediated Transcriptional Repression of c- myc Is Dependent on Direct Binding of Smad3 to a Novel Repressive Smad Binding Element , 2022 .